Clinical trials: Androgens
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than…
- Trial name
- NCT02742675
- Testing
- Bicalutamide, goserelin acetate, flutamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
High Risk Prostate Cancer
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
This is a phase 2, open-label, randomized study of adjuvant treatment in subjects with high-risk prostate cancer who are candidates for RP with PLND based on M0 status at conventional imaging, but staged as oligometastatic with…
- Trial name
- STAPLE (NCT06758882)
- Testing
- Apalutamide, Androgen receptor (AR) inhibitor
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Marco Oderda
Hypogonadism, Male, Testosterone Deficiency
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
This study relates to men with hypogonadism, a condition describing a deficiency of androgens such as testosterone. Deficiency of these hormones occurs in men due to testicular (primary) or hypothalamic-pituitary (secondary)…
- Conditions
- Hypogonadism, Male, Testosterone Deficiency, Prostate Cancer, Androgen Deficiency
- Trial name
- MMetdMH (NCT05773183)
- Testing
- Testosterone, GnRH
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Transgenderism, Reproductive Issues
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.
- Trial name
- NCT07092527
- Testing
- Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Bone Loss
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism.
- Trial name
- NCT00199537
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT00544830
- Testing
- Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer
The overall goal of this pilot project is to test the hypothesis that a decline in muscle strength precedes the decline in bone strength in men undergoing androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- NCT03386812
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Texas Southwestern Medical Center
COVID-19
The South Proxa-Rescue AndroCoV Trial Against COVID-19
The purpose of this study is to investigate the efficacy of proxalutamide or hospitalized moderate-to-severe COVID-19 patients.
- Trial name
- NCT05126628
- Testing
- Proxalutamide
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- Corpometria Institute
Prostatic Neoplasms
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
This study will determine the maximum dose of docetaxel that can be given safely in combination with ketoconazole for treating advanced prostate cancer.
- Trial name
- NCT00032825
- Testing
- Ketaconazole, Docetaxel
- Where
- United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
High-risk Prostate Cancer
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients
Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional…
- Trial name
- CHIRP (NCT01488968)
- Testing
- Standard Radiation Treatment, Hypofractionated radiation treatment
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer, Mild Cognitive Impairment
PET Imaging in MCI Following ADT for PCa
Mild cognitive impairment (MCI) with ageing is thought in part to be related to reduced serum sex hormones which is well-recognized, especially in females, but poorly understood.
- Trial name
- NCT02061345
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06305598
- Testing
- Biopsy, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
The primary objective of this study is: To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: To…
- Trial name
- NCT00273338
- Testing
- calcitriol, docetaxel
- Where
- 222 sites in United States, Canada and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Novacea
Breast Cancer
of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation
Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages.
- Trial name
- NCT05404334
- Testing
- Androgen receptor status and BRCA mutation
- Where
- India
- Volunteers
- 231 people
- Sponsor
- Banaras Hindu University
Androgen Deficiency, AD
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
The purpose of this study is to find out if androgen deficiency (low levels of testosterone, a male hormone produced by the sex glands) and erectile dysfunction (sexual dysfunction) will predict over time the development of a…
- Conditions
- Androgen Deficiency, AD, Erectile Dysfunction, ED
- Trial name
- HEART-MEND (NCT01190904)
- Where
- 5 sites in United States
- Volunteers
- 568 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Adenocarcinoma of the Prostate
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2).
- Trial name
- NCT00520481
- Testing
- IMC-A12 (Cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
- Trial name
- ARMOR3-SV (NCT02438007)
- Testing
- Galeterone, Enzalutamide
- Where
- 117 sites in United States, Australia and 6 more
- Volunteers
- 953 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.